Comparative analysis of the efficacy of Biktarvy and Doveto

Biktarvy and Dovato are both antiviral drugs currently used clinically to treat human immunodeficiency virus (HIV) infection. They are single-piece compound preparations designed to simplify treatment regimens and improve patient compliance. Although the two have the same basic goal of treating HIV, there are certain differences in ingredient combinations, indications and efficacy performance, which require specific analysis to help clinical selection.

Bictegravir is composed of three ingredients: bictegravir, emtricitabine and tenofovir alafenamide (TAF), and has the ability to highly inhibit viral replication. Its core component, biclutamide, is a new generation of integrase inhibitor that can effectively block the integration of HIV viral DNA into the host genome and reduce the risk of drug resistance. Emtricitabine and tenofovir alafenamide, as nucleoside reverse transcriptase inhibitors, synergistically enhance the antiviral effect. Bituvi is suitable for treatment-naïve patients and those with poor viral replication suppression. Clinical studies have shown that it has a high viral suppression rate and is well tolerated.

Doveto is composed of two ingredients, dolutegravir and lamivudine, and is a two-drug regimen. Dolutegravir, another highly effective integrase inhibitor, has excellent performance in inhibiting HIV replication and has a high resistance threshold. Lamivudine, as a nucleoside reverse transcriptase inhibitor, assists in improving antiviral effects. Doveto is suitable for HIV patients who have no history of antiviral treatment and no drug-resistant mutations. It is especially suitable for patients with low viral load or good physical fitness at the beginning of treatment. Its simplified two-drug regimen helps reduce drug exposure and potential side effects.
From the perspective of efficacy, Bituvain contains three drug ingredients, which theoretically has wider coverage and stronger inhibitory effect on multiple virus strains. It is especially suitable for patients with high viral load, complex treatment experience or risk of drug resistance. Doveto is known for its simplified treatment and is suitable for patients with early diagnosis and no complicated medical history. Clinical trials have shown that it is equivalent to the traditional three-drug regimen in terms of viral suppression rate and immune recovery. Which option to choose should be comprehensively judged based on the patient's specific situation, drug resistance test results and doctor's recommendations.
Reference: https://www.biktarvy.com/